Vertex stock popped Tuesday — while shares of rival Maze Therapeutics (MAZE) skyrocketed — on a surprise expansion for their kidney disease drugs. Both companies are working on treatments for ...
Vertex's strategy is simple. The company develops innovative medicines for diseases with high unmet needs, particularly (though not always) rare conditions. There are advantages and disadvantages to ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Management raised full-year 2026 total revenue guidance to “$13.1 billion to $13.2 billion,” with CFO Wagner saying the outlook “reflects continued strong performance from the CF franchise, including ...
Hosted on MSN
How to find the vertex of a parabola in vertex form
👉 Learn how to graph quadratic equations in vertex form. A quadratic equation is an equation of the form y = ax^2 + bx + c, where a, b, and c are constants. The graph of a quadratic equation is in ...
Vertex has struck a $10 billion deal—its largest ever—to gain endocrine disease specialist Crinetics and two of its drugs that have combined peak sales potential ...
To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min The deal for Crinetics ...
Allison covers what hot startups are getting up to, and who’s financing them. She is also co-host of the weekly biotech podcast, “The Readout Loud.” You can reach Allison on Signal at AllisonDeAngelis ...
CNBC's Angelica Peebles reports on Vertex Pharmaceuticals' acquisition of Crinetics. Got a confidential news tip? We want to hear from you. Sign up for free newsletters and get more CNBC delivered to ...
Vertex offers $85 per Crinetics share, a 102% premium to stock's Monday close Deal gives access to Palsonify, an FDA-approved oral pill for adult acromegaly Vertex expects deal to become accretive to ...
The platform was built in collaboration with Vertex Pharmaceuticals, a biopharma company that launched the non-opioid pain reliever, Journavx, in early 2025. (Karola G / Pexels) Cloud-based ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results